Basic Information
Kyntheum
Regulatory Information
EMEA/H/C/003959
Authorised
July 17, 2017
November 10, 2016
6
January 10, 2023
Company Information
Denmark
Industriparken 55 DK-2750 Ballerup
LEO Pharma A/S
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Kyntheum is indicated for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy.
Overview Summary
This is a summary of the European public assessment report (EPAR) for Kyntheum. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Kyntheum. For practical information about using Kyntheum, patients should read the package leaflet or contact their doctor or pharmacist.